Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate after Sen. Bernie Sanders threatened to subpoena the company over the pricing of diabetes and obesity drugs. The Senate health committee announced the agreement after a public back-and-forth. Jørgensen’s appearance is a pivot from initially scheduling a vote to subpoena Novo’s U.S. division chief. The hearing is set for early September, with Sanders demanding an explanation for high drug prices in the U.S. Novo defended its pricing, citing potential health benefits and decreasing net prices. This capitulation is part of Sanders’ tactic of using subpoenas to bring pharmaceutical executives to hearings.
Source link
Novo Nordisk CEO to testify on Ozempic, Wegovy cost
